New drug formulations tested in healthy volunteers
NCT ID NCT06911567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested different versions of the drug TEV-56286 (emrusolmin) in 47 healthy adults to see how well the body absorbs each form. Participants took a single dose of either a new formulation or a reference capsule, and researchers measured drug levels in the blood. The goal was to compare the formulations and check for any safety issues over about 70 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Emrusolmin (TEV-56286)
- What this could lead to
- If successful, this could help determine the best way to deliver emrusolmin in future studies, potentially leading to better treatments for conditions it targets.
- What could go wrong
- This is an early-stage trial in healthy volunteers, not patients. It only measures drug levels and short-term safety, so it cannot predict if the drug will work for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Teva Investigational Site 12141
Miramar, Florida, 33025, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates